Cross talk of HIF1α/YB-1 in promotes metastasis of Ewing sarcoma

crossMark

 

Research Article
Journal of Cellular Cancer  Volume 1, Issue 1, pages 1-9
Published: December 15, 2009

Mika H. Matsuzaki, Simon F. Kingstone, Jaroslaw Umemura

Abstract

Ewing sarcoma (ES) is a part of a larger family of round blue-cell tumors that a large body of literature exists on ES of bone. Highly metastatic cancers that most often strike teens, and can be found in younger children and adults. Recent research has added numerous new proteins than can direct the metastatic process either directly or indirectly by inducing type of protein leading to death in cancer patients. Among them Y-box–binding protein-1 (YB-1) is a recently identified protein known to induce metastasis in different cancers. YB-1 mainly involved in regulation of mRNA transcription, splicing, translation, and stability. However, the molecular mechanisms underlying these biological behaviors have not been completely elucidated. In this study, we investigate the molecular mechanism by which YB-1 promote HIF1α-induced invasion and metastasis of Ewing sarcoma.

Keywords: Ewing sarcoma; Y-box–binding protein-1; Hypoxia-inducible factor 1α

Article citationReferencesFull-Text/PDFFeedback
The citation data is computed by the crossref service:

citedby

References

  1. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing’s family tumors. Oncogene 2001; 20:5747–5754. [PubMed]
  2. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 2003; 348: 694–701. [PubMed]
  3. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle 2008; 7:250–256. [PubMed]
  4. Lessnick SL, Dacwag CS, Golub TR. The Ewing’s sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 2002; 1:393–401. [PubMed]
  5. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 6:415–428. [PubMed]
  6. Kuwano M, Uchiumi T, Hayakawa H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94:9–14. [PubMed]
  7. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003; 25:691–698. [PubMed]
  8. Giménez-Bonafé P, Fedoruk MN, Whitmore TG, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 2004; 59:337–349. [PubMed]
  9. Shiota M, Izumi H, Onitsuka T, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008; 68:98–105. [PubMed]
  10. Bader AG, Vogt PK. Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation. Mol Cell Biol 2005; 25:2095–2106. [PubMed]
  11. Bader AG, Vogt PK. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene 2008; 27:1179–1182. [PubMed]
  12. Lamouille S, Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007; 178:437–451. [PubMed]
  13. Mertens PR, Harendza S, Pollock AS, Lovett DH. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 1997; 272:22905–22912. [PubMed]
  14. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. Nat. Genet 1997; 17:495–497.
  15. Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy–a report from the Children’s Oncology Group. Pediatr. Blood Cancer 2007; 49:894–900.
  16. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing’s’s sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007; 459:40–47. [PubMed]
  17. Mitsiades N, Poulaki V, Leone A, Tsokos M. Fas-mediated apoptosis in Ewing’s sarcoma cell lines by metalloproteinase inhibitors. J Natl Cancer Inst 1999; 91:1678–1684. [PubMed]
  18. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721–32. [PubMed]
  19. Hattinger CM, Potschger U, Tarkkanen M, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br. J. Cancer 2002; 86:1763–1769. [PubMed]
  20. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 2000; 88:2606–2618. [PubMed]
  21. Metzen E, Stiehl DP, Doege K, Marxsen JH, Hellwig-Bürgel T, Jelkmann W. Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: Identification of a functional hypoxia-responsive element. Biochem. J 2005; 387:711–717. [PubMed]
  22. Hanze J, Eul BG, Savai R, et al. RNA interference for HIF-1alpha inhibits its downstream signalling and affects cellular proliferation. Biochem. Biophys. Res. Commun 2003; 312:571–577. [PubMed]
  23. Ahrens S, Hoffmann C, Jabar S, et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999; 32:186–195.
  24. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 2000;18:3108–3114. [PubMed]
  25. Hattinger CM, Rumpler S, Strehl S, et al. Prognostic Impact of Deletions at 1p36 and Numerical Aberrations in Ewing Tumors. Genes Chromosomes Cancer 1999;24:243–254. [PubMed]
  26. Zielenska M, Zhang ZM, Ng K, et al. Acquisition of secondary structural chromosomal changes in pediatric Ewing’s sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer 2001; 91:2156–2164. [PubMed]
  27. Zhong H, Semenza GL, Simons JW, de Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev 2004; 28:88–93. [PubMed]
  28. Zhong H, Semenza GL, Simons JW, de Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev 2004; 28:88–93.

READ THE FULL ARTICLE

1. Access this article through Open Athens

2. Access this article through your login credentials or your institution

Get Access

3. Purchase this article at rate $55.00 and received Full-Text/PDF

Purchase Article

You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, PayPal will be asked to supply your billing card information. Before continue with your purchase please read carefully BM–Publisher terms and conditions of purchase.

For any technique error please contact us and will be a response to sending purchase article by email.

Thank you for visiting Pathophysiology of Cell Injury Journal. * = Required fields

Your Name (required)

Your Email (required)

Subject

Your Message